<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311425526</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311425526</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sustained remission of systemic lupus erythematosus related calciphylaxis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mallett</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203311425526"/>
</contrib>
<contrib contrib-type="author">
<name><surname>John</surname><given-names>GT</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ranganathan</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kark</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Berquier</surname><given-names>I</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Casey</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Healy</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Francis</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425526">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203311425526"><sup>1</sup>Department of Renal Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Australia; and <sup>2</sup>Department of Pathology, Royal Brisbane and Women’s Hospital, Brisbane, Australia</aff>
<author-notes>
<corresp id="corresp1-0961203311425526">Andrew Mallett, Department of Renal Medicine, Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, Queensland, 4029, Australia Email: <email>andrew.mallett@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>441</fpage>
<lpage>444</lpage>
<history>
<date date-type="received"><day>1</day><month>6</month><year>2011</year></date>
<date date-type="accepted"><day>31</day><month>8</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Calciphylaxis continues to present a clinical challenge for patient management. As in this case, it can be associated with connective tissue disease (CTD) such as systemic lupus erythematosus (SLE). Unlike previous reported cases, long-term remission has been attained. This provides some insight into methods of therapy as well as potential pathogenic models for this disease.</p>
</abstract>
<kwd-group>
<kwd>calciphylaxis</kwd>
<kwd>remission</kwd>
<kwd>SLE</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311425526"><title>Background</title>
<p>Calciphylaxis is associated with significant morbidity and mortality amongst affected patients. It is a calcifying disease of small cutaneous blood vessels of unclear pathogenesis. In some patients connective tissue disease has been implicated. Here we present a case of systemic lupus erythematosus (SLE) related calciphylaxis occurring in a patient with end-stage renal disease (ESRD) secondary to lupus nephritis, for which durable remission has been attained. Whilst cases of calciphylaxis resolution have been reported, this is the first reported case of durable resolution in the setting of SLE.</p></sec>
<sec id="sec2-0961203311425526" sec-type="cases"><title>Case report</title>
<p>This 30-year old Caucasian female, MW, was transferred for management of clinically and histologically diagnosed calciphylaxis. Her history was of end-stage renal disease secondary to class 4 lupus nephritis, treated with continuous ambulatory peritoneal dialysis for two years and intermittent hemodialysis for a year prior to that. SLE was diagnosed 17 years ago, and she was maintained with oral prednisolone 7.5 mg daily with persistent intermittent symmetrical small joint arthralgias. She had a past history of autoimmune hemolytic anemia resistant to steroid and cyclophosphamide therapies, lupus anticoagulant antibody (LAA) positivity without thrombosis, and seizure disorder controlled with oral sodium valproate.</p>
<p>Two weeks prior to admission to hospital, three blisters appeared on the distal left leg followed by worsening severe pain, local necrosis (<xref ref-type="fig" rid="fig1-0961203311425526">Figure 1a</xref>), and doubling in number within one week. Investigations revealed a low parathyroid hormone level (&lt;0.5 pmol/L), normal corrected calcium level (2.42 mmol/L), mildly raised phosphate (1.90 mmol/L), and normal 25-OH cholecalciferol (88 nmol/L). ANA (160 homogenous/640 speckled), RNP and anti DS-DNA (19 IU) were positive, with low C3 (0.48 g/L) and C4 (0.05 g/L). Whilst LAA, anti-Beta2 glycoprotein and thrombophilia screen was negative, anti-cardiolipin antibody (ACA) was positive (10 U/ml) and has remained positive. LAA has been positive once previously.
<fig id="fig1-0961203311425526" position="float"><label>Figure 1</label><caption><p>a. Initial presentation; 91 mm × 101 mm (300 × 300 DPI). b. Eleven months after presentation; 116 mm × 82 mm (300 × 300 DPI).</p></caption><graphic xlink:href="10.1177_0961203311425526-fig1.tif"/></fig></p>
<p>Peritoneal dialysis remained adequate and stable with urea 14–16 mmol/L, creatinine 550–660 mmol/L. The patient remained euvolemic.</p>
<p>Two punch biopsies of the lesion performed prior to transfer were diagnostic of calciphylaxis with significant superficial and deep vascular calcification and epidermal/dermal necrosis (<xref ref-type="fig" rid="fig2-0961203311425526">Figure 2a</xref>). No microvascular thrombi were present.
<fig id="fig2-0961203311425526" position="float"><label>Figure 2</label><caption><p>a. Initial presentation, von Kossa stain, × 100 magnification; 903 mm × 677 mm (72 × 72 DPI). b. Six months after presentation, von Kossa stain, × 100 magnification; 903 mm × 677 mm (72 × 72 DPI).</p></caption><graphic xlink:href="10.1177_0961203311425526-fig2.tif"/></fig></p>
<p>The clinical impression was of calciphylaxis. The underlying etiology was thought to be a combination of chronic active SLE and endothelial activation with ACA occurring in the hyperphosphatemic and hyperuremic milieu of ESRD. Lupus activity was assessed clinically by symptomatology and biochemistry.</p>
<p>She was treated with oral sevelamer 1600 mg thrice daily, intraperitoneal sodium thiosulfate 25 g alternate days in long-dwell intraperitoneal bags, hyperbaric treatments five days per week for 30 sessions, and specialist wound care nursing. Previous aluminium hydroxide 600 mg BD and calcium phosphate 1 g BD oral phosphate binding therapy was ceased. Vitamin D supplementation was absent throughout. Intraperitoneal sodium thiosulfate was down-titrated after three doses to 12.5 g on alternate days due to nausea and stopped after six weeks of treatment due to nausea and partial skin lesion healing. Active SLE was treated with the introduction of mycophenolate sodium 720 mg orally BD and hydroxychloroquine 200 mg, and prednisolone was up-titrated to 15 mg. Aspirin 100 mg was commenced given past LAA and current ACA positivity. Neither warfarin nor iron therapies were used previously nor subsequently.</p>
<p>The lesions healed (<xref ref-type="fig" rid="fig1-0961203311425526">Figure 1b</xref>) and SLE became inactive. Six months after commencement of therapy, skin biopsy was performed for a lesion. The histopathological findings were not pathognomonic of calciphylaxis. No calcification or necrosis was identified; however, in some deep dermal vessels minimal Von Kossa positive material was seen (<xref ref-type="fig" rid="fig2-0961203311425526">Figure 2b</xref>). The lesion healed spontaneously within a week without recurrence or increased SLE activity. MW has subsequently had a successful pregnancy and postpartum SLE flare, both managed without recurrence of calciphylactic lesions. Serum corrected calcium (2.22–2.54 mmol/L) has remained essentially normal; however, serum phosphate has varied somewhat (1.4–3.19 mmol/L) and is presently similar to the level at calciphylaxis diagnosis (1.51 mmol/L). Parathyroid hormone levels have increased in a sustained fashion (43–118 pmol/L).</p></sec>
<sec id="sec3-0961203311425526" sec-type="discussion"><title>Discussion</title>
<p>This report is instructive in many ways. It reaffirms calciphylaxis as a differential diagnosis for skin lesions in patients with renal disease and connective tissue disease (CTD). The pathogenesis in these circumstances is more complex. This is the first reported case of lupus-related calciphylaxis in which durable remission has been achieved, outside of the context of experimental hematopoietic stem cell transplantation for severe SLE.<sup><xref ref-type="bibr" rid="bibr1-0961203311425526">1</xref></sup> One case reported in Saudi Arabia resulted in death within three months,<sup><xref ref-type="bibr" rid="bibr2-0961203311425526">2</xref></sup> and another patient as part of a case series in South Australia died nine months after showing initial clinical improvement.<sup><xref ref-type="bibr" rid="bibr3-0961203311425526">3</xref></sup> Another report of calciphylaxis secondary to demonstrated cutaneous microvascular thrombosis in a patient with SLE and antiphospholipid syndrome reported partial resolution after amputation.<sup><xref ref-type="bibr" rid="bibr4-0961203311425526">4</xref></sup></p>
<p>Vitamin D, serum phosphate, and serum calcium were not significantly abnormal in this case. There are reported cases of SLE-related calciphylaxis with essentially normal serum vitamin D, calcium, phosphate,<sup><xref ref-type="bibr" rid="bibr5-0961203311425526">5</xref></sup> and parathyroid hormone levels<sup><xref ref-type="bibr" rid="bibr1-0961203311425526">1</xref></sup> though not all four concomitantly. Calcium–phosphate axis disturbance to some degree is universal. In this case transient suppressed parathyroid hormone levels were observed. Hypoparathyroidism may have been due to an autoimmune pathology in keeping with intercurrent active SLE. Anti-calcium sensing receptor (CaSR) antibodies were not tested for but their hypoparathyroid effect can be reversible.<sup><xref ref-type="bibr" rid="bibr6-0961203311425526">6</xref></sup> Resultant hypophosphaturia may have contributed to further dynamic disturbance of the calcium–phosphate axis and thus precipitation of calciphylaxis.</p>
<p>Whilst the pathogenesis of calciphylaxis is unknown, this case report suggests that an inciting process such as active SLE may play a role in either the initiation or acceleration of calciphylaxis in some patients. The hypothesis that active SLE plays a role in inducing vascular inflammation and subsequent vascular calcification resulting in calciphylaxis has been previously reported.<sup><xref ref-type="bibr" rid="bibr1-0961203311425526">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203311425526">2</xref>,<xref ref-type="bibr" rid="bibr7-0961203311425526">7</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr9-0961203311425526">9</xref></sup> This case adds to this and hints at the postulated ‘two hit’ pathogenetic model,<sup><xref ref-type="bibr" rid="bibr10-0961203311425526">10</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr14-0961203311425526">14</xref></sup> which here involves autoimmune vascular inflammation and uremic calcium–phosphate axis disruption.</p>
<p>This case also provides some anecdotal evidence that calciphylaxis can be successfully medically treated in patients with active SLE. This may require multifaceted therapy including hyperbaric treatment, sodium thiosulfate, optimized calcium/phosphate balance, optimized renal replacement therapy, and assessment of CTD activity with appropriate immunosuppression.</p></sec>
</body>
<back><ack>
<title>Acknowledgments</title>
<p>Results presented in this paper have not been published previously in whole or part. The patient has provided informed consent for publication.</p>
<sec id="sec4-0961203311425526"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<sec id="sec5-0961203311425526"><title>Conflict of interest statement</title>
<p>None to declare.</p></sec></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311425526"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandelbrot</surname><given-names>DA</given-names></name><name><surname>Santos</surname><given-names>PW</given-names></name><name><surname>Burt</surname><given-names>PK</given-names></name><etal/></person-group>. <article-title>Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation</article-title>. <source>Nephrol Dial Transplant</source> <year>2008</year>; <volume>23</volume>: <fpage>2679</fpage>–<lpage>2684</lpage>.</citation></ref>
<ref id="bibr2-0961203311425526"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Beladi</surname><given-names>FI</given-names></name></person-group>. <article-title>Catastrophic calciphylaxis in a patient with lupus nephritis and recent onset of end-stage renal disease</article-title>. <source>Saudi J Kidney Dis Transpl</source> <year>2010</year>; <volume>21</volume>: <fpage>323</fpage>–<lpage>327</lpage>.</citation></ref>
<ref id="bibr3-0961203311425526"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>NM</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Teubner</surname><given-names>DJO</given-names></name><name><surname>Coates</surname><given-names>PTH</given-names></name></person-group>. <article-title>Hyperbaric oxygen as effective adjuvant therapy in the treatment of distal calcific uraemic arteriolopathy</article-title>. <source>NDT Plus</source> <year>2008</year>; <volume>4</volume>: <fpage>244</fpage>–<lpage>249</lpage>.</citation></ref>
<ref id="bibr4-0961203311425526"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JJ</given-names></name><name><surname>Laumann</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name></person-group>. <article-title>Calciphylaxis and antiphospholipid antibody syndrome</article-title>. <source>J Am Acad Dermatol</source> <year>2000</year>; <volume>42</volume>: <fpage>849</fpage>–<lpage>849</lpage>.</citation></ref>
<ref id="bibr5-0961203311425526"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zechlinski</surname><given-names>JJ</given-names></name><name><surname>Angel</surname><given-names>JR</given-names></name></person-group>. <article-title>Calciphylaxis in the absence of renal disease: secondary hyperparathyroidism and systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2009</year>; <volume>36</volume>: <fpage>2370</fpage>–<lpage>2371</lpage>.</citation></ref>
<ref id="bibr6-0961203311425526"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kifor</surname><given-names>O</given-names></name><name><surname>McElduff</surname><given-names>A</given-names></name><name><surname>LeBoff</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>; <volume>89</volume>: <fpage>548</fpage>–<lpage>556</lpage>.</citation></ref>
<ref id="bibr7-0961203311425526"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igaki</surname><given-names>N</given-names></name><name><surname>Moriguchi</surname><given-names>R</given-names></name><name><surname>Hirota</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Calciphylaxis in a patient with end-stage renal disease secondary to systemic lupus erythematosus associated with acral gangrene and mesenteric ischemia</article-title>. <source>Intern Med</source> <year>2001</year>; <volume>40</volume>: <fpage>1232</fpage>–<lpage>1237</lpage>.</citation></ref>
<ref id="bibr8-0961203311425526"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slough</surname><given-names>S</given-names></name><name><surname>Servilla</surname><given-names>KS</given-names></name><name><surname>Harford</surname><given-names>AM</given-names></name><name><surname>Konstantinov</surname><given-names>KN</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Tsamaloukas</surname><given-names>AH</given-names></name></person-group>. <article-title>Association between calciphylaxis and inflammation in two patients on chronic dialysis</article-title>. <source>Adv Perit Dial</source> <year>2006</year>; <volume>22</volume>: <fpage>171</fpage>–<lpage>174</lpage>.</citation></ref>
<ref id="bibr9-0961203311425526"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Naguwa</surname><given-names>SM</given-names></name><name><surname>Cheema</surname><given-names>G</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name></person-group>. <article-title>Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis</article-title>. <source>Autoimmun Rev</source> <year>2008</year>; <volume>7</volume>: <fpage>638</fpage>–<lpage>643</lpage>.</citation></ref>
<ref id="bibr10-0961203311425526"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selye</surname><given-names>H</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Strebel</surname><given-names>R</given-names></name></person-group>. <article-title>Sensitization to calciphylaxis by endogenous parathyroid hormone</article-title>. <source>Endocrinology</source> <year>1962</year>; <volume>71</volume>: <fpage>554</fpage>–<lpage>558</lpage>.</citation></ref>
<ref id="bibr11-0961203311425526"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilmer</surname><given-names>WA</given-names></name><name><surname>Magro</surname><given-names>CM</given-names></name></person-group>. <article-title>Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment</article-title>. <source>Semin Dial</source> <year>2002</year>; <volume>15</volume>: <fpage>172</fpage>–<lpage>186</lpage>.</citation></ref>
<ref id="bibr12-0961203311425526"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>NM</given-names></name><name><surname>Teubner</surname><given-names>DJ</given-names></name><name><surname>Coates</surname><given-names>PT</given-names></name></person-group>. <article-title>Calcific uremic arteriolopathy: advances in pathogenesis and treatment</article-title>. <source>Semin Dial</source> <year>2007</year>; <volume>20</volume>: <fpage>150</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr13-0961203311425526"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Goldsmith</surname><given-names>DJ</given-names></name></person-group>. <article-title>Sodium thiosulfate: new hope for the treatment of calciphylaxis</article-title>. <source>Semin Dial</source> <year>2010</year>; <volume>23</volume>: <fpage>258</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr14-0961203311425526"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farah</surname><given-names>M</given-names></name><name><surname>Crawford</surname><given-names>RI</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Chan Yan</surname><given-names>C</given-names></name></person-group>. <article-title>Calciphylaxis in the current era: emerging ‘ironic’ features?</article-title> <source>Nephrol Dial Transplant</source> <year>2011</year>; <volume>26</volume>: <fpage>191</fpage>–<lpage>195</lpage>.</citation></ref>
</ref-list>
</back>
</article>